Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
